{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-23-000091","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.580981+00:00","generated_at":"2026-06-15T00:49:26.766062+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emergent BioSolutions closes sale of travel health business to Bavarian Nordic for $270M upfront","bullets":["Emergent closed sale of travel health business to Bavarian Nordic on May 15, 2023 for $270M upfront cash.","Potential milestone payments: up to $80M for CHIKV VLP development/approval and $30M earnout on 2026 net sales.","Assets sold include typhoid vaccine Vivotif, cholera vaccine Vaxchora, CHIKV VLP candidate, Bern manufacturing site, San Diego development facilities.","Majority of employees supporting these products and facilities are joining Bavarian Nordic."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-23-000091","json":"https://secwatch.observer/filing/0001367644-23-000091.json","markdown":"https://secwatch.observer/filing/0001367644-23-000091.md","text":"https://secwatch.observer/filing/0001367644-23-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/0001367644-23-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/ebs-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:49:26.766062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc476ee335f6d7be35a140a5534fdb53bcdf6e69","claim":"Emergent BioSolutions Inc. completed a disposition involving Bavarian Nordic for $270 million (closed 2023-05-15).","evidence_excerpt":"the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. At the closing, Buyer paid a cash purchase price of $270 million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing (the \"Purchase Price\"). Bavarian Nordic","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/0001367644-23-000091-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Bavarian Nordic"},{"label":"Consideration","value":"$270 million"},{"label":"Closing","value":"2023-05-15"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}